BioReliance (Merck) vs Charles River Laboratories: CDMO Comparison
Side-by-side comparison of BioReliance (Merck) and Charles River Laboratories on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Charles River Laboratories has more FDA inspections on record (7 vs 2) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Charles River Laboratories holds 9 active EMA GMP certificates; BioReliance (Merck) does not appear in EudraGMDP.
- BioReliance (Merck) has stronger MHRA / UK coverage (8 compliant certificates vs 2).
- Composite Signal Score: Charles River Laboratories 92/100 vs BioReliance (Merck) 81/100 — a 11-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both BioReliance (Merck) and Charles River Laboratories qualify as AAV manufacturers; Charles River Laboratories carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both BioReliance (Merck) and Charles River Laboratories qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: BioReliance (Merck) vs Charles River Laboratories
Which has the stronger FDA inspection record, BioReliance (Merck) or Charles River Laboratories?
Both BioReliance (Merck) and Charles River Laboratories maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. BioReliance (Merck) has 2 FDA inspections on record; Charles River Laboratories has 7.
How do BioReliance (Merck) and Charles River Laboratories compare on European GMP coverage?
BioReliance (Merck) holds 0 active EMA GMP certificates and 8 MHRA / UK certificates. Charles River Laboratories holds 9 active EMA GMP certificates and 2 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — BioReliance (Merck) or Charles River Laboratories?
Both BioReliance (Merck) and Charles River Laboratories are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
BioReliance (Merck) carries a Signal Score of 81/100 and Charles River Laboratories carries 92/100 — a meaningful lead for Charles River Laboratories. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →